Illumina Inc (ILMN)
What changed in recent filings
- Revenue +9% YoYQuarter ended Jun 28, 2026
- Institutions — 5 new · 3 reduced13F · as of end of 2026 Q2
- Free cash flow declined recentlyDec 28, 2025 → Jun 28, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Illumina Inc
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 6 → 2026 Q2: 9 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Illumina Inc
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Co0.21% of portfolio · held as of 2019 Q1 or earlier
- ARK Invest1.19% of portfolio · since 2024 Q4
- Bridgewater Associates0.01% of portfolio · since 2026 Q1
- Point72 Asset Management0.01% of portfolio · since 2026 Q1
- PRIMECAP Management0.37% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.12% of portfolio · held as of 2026 Q2 or earlier
- Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
- National Pension Service (Korea)0.04% of portfolio · held as of 2026 Q2 or earlier
- Capital World Investors0.32% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Illumina. The world's No. 1 in next-generation gene-sequencing equipment. It provides core infrastructure for the precision-medicine and genetic-diagnostics markets.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Illumina Inc is classified under the Biotech & Health sector. See peers below.
Illumina Inc key financials
Based on SEC filings · as of Jun 28, 2026
Tap a metric name to see its meaning in the glossary.
Illumina Inc vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ILMN revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-28 revenue was $1.2B, +9.4% YoY.
The largest segment is Sequencing, 90.9% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the Sequencing segment (about 82% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Illumina Inc
Per SEC N-PORT · 2026-04-30 · by weight · factual
ILMN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
ILMN FAQ
What is Illumina Inc (ILMN)?
Illumina. The world's No. 1 in next-generation gene-sequencing equipment. It provides core infrastructure for the precision-medicine and genetic-diagnostics markets.
What sector is Illumina Inc in?
Illumina Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Illumina Inc's key financials?
As of Jun 28, 2026 in SEC filings: Revenue growth (YoY) 4.9%, Operating margin 21.1%, Net margin 18.4%, ROE 31.2%. Definitions and interpretation are available on Stocklore.
What are Illumina Inc's main revenue segments?
The largest segment is Sequencing, about 90.9% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Illumina Inc (ILMN) stock?
On Stocklore you can see ILMN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.